Core Viewpoint - Bioventus Inc. will report its financial results for the fourth quarter of fiscal year 2025 on March 5, 2026, and will host a conference call to discuss these results and provide a business update [1]. Group 1 - The financial results will be announced before the market opens on March 5, 2026 [1]. - A conference call will take place at 8:30 a.m. Eastern Time on the same day to discuss the results [1]. - Participants can join the conference call by dialing 1-833-636-0497 and referring to the Bioventus Inc. Conference Call [2]. Group 2 - Bioventus is focused on delivering clinically proven, cost-effective products that aid in quick and safe healing [3]. - The company's mission is to help patients resume and enjoy active lives through its innovations in Pain Treatments, Restorative Therapies, and Surgical Solutions [3]. - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians globally [3].

Core Viewpoint - Bioventus Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its innovations in active healing [1] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [2] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [2] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [2]

Core Points - Bioventus Inc. will present at the Piper Sandler Healthcare Conference on December 3, 2025, at 10:10 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Viewpoint - Bioventus Inc. will report its financial results for Q3 of fiscal year 2025 on November 4, 2025, and will host a conference call to discuss these results and provide a business update [1]. Financial Reporting - The financial results will be announced before the market opens on November 4, 2025 [1]. - A conference call is scheduled for 8:30 a.m. Eastern Time on the same day to discuss the results [1]. Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2]. - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until November 3, 2026 [2]. Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that aid in quick and safe healing [3]. - The company's mission focuses on helping patients resume active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3]. - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3].

Core Insights - Bioventus Inc. will participate in the Morgan Stanley Global Healthcare Conference on September 10, 2025, with CFO Mark Singleton speaking [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Insights - Bioventus Inc. is a global leader in innovations for active healing and will have its President and CEO, Rob Claypoole, participate in a fireside chat at the Canaccord Genuity Global Growth Conference on August 12, 2025 [1] - A live webcast of the presentation will be available on the company's website, along with a replay option after the event [2] Company Overview - Bioventus delivers clinically proven and cost-effective products aimed at helping individuals heal quickly and safely, with a mission to assist patients in resuming active lives [3] - The company's offerings include Pain Treatments, Restorative Therapies, and Surgical Solutions, all built on high quality standards and evidence-based medicine [3] - Bioventus is recognized as a trusted partner for physicians globally, emphasizing strong ethical behavior in its operations [3]

Core Viewpoint - Bioventus Inc. has secured a $400 million Senior Secured Credit Agreement, which includes a $300 million term loan and a $100 million revolving credit facility, aimed at enhancing liquidity and financial flexibility [1][2][3]. Group 1: Credit Agreement Details - The new Credit Agreement increases the revolving credit facility from $40 million to $100 million compared to the previous 2019 Credit Agreement [2]. - The interest margin has been reduced by 75 basis points, resulting in over $2 million in annual interest expense savings [2]. - The annual amortization on the term loan has been lowered from 10% to 5% for the duration of the loan [2]. Group 2: Financial Impact and Use of Proceeds - The proceeds from the Credit Agreement were utilized to repay the outstanding loan balance of $333 million under the 2019 Credit Agreement [3]. - The repayment was accomplished using $30 million drawn from the new revolving credit facility, $3 million in cash from the balance sheet, and the new $300 million term loan [3]. Group 3: Company Overview - Bioventus is recognized for delivering clinically proven, cost-effective products that facilitate quick and safe healing, with a mission to help patients resume active lives [4]. - The company focuses on innovations for active healing, including pain treatments, restorative therapies, and surgical solutions [4].

Core Insights - Bioventus Inc. will report its financial results for Q2 of fiscal year 2025 on August 6, 2025, before market opening [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Company Overview - Bioventus is a global leader in innovations for active healing, delivering clinically proven and cost-effective products that aid in quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Viewpoint - Bioventus Inc. will report its financial results for Q1 of fiscal year 2025 on May 6, 2025, before market opening, followed by a conference call for discussion [1] Group 1: Financial Reporting - The financial results for the first quarter of fiscal year 2025 will be announced before the market opens on May 6, 2025 [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Group 2: Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2] - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until May 5, 2026 [2] Group 3: Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products for quick and safe healing [3] - The company's mission focuses on helping patients resume active lives through offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Insights - Bioventus Inc. reported a fourth-quarter adjusted EPS of 15 cents, an increase from 7 cents, surpassing the consensus estimate of 8 cents [1] - The company achieved sales of $153.6 million, reflecting a year-over-year growth of 13.5%, exceeding the consensus of $145.2 million, driven by strong performance in pain treatments and surgical solutions [1] Sales Performance - Pain treatment sales rose by 18.7% to $62.8 million, while Surgical Solutions sales increased by 16.8% to $46.43 million; however, Restorative Therapies sales saw a slight decline of 0.6% to $25.95 million [2] - The net loss from continuing operations was reduced to $0.3 million from $7.7 million a year ago, indicating improved financial health [2] - Adjusted EBITDA from continuing operations reached $28.3 million, a 28.3% increase from $22.0 million last year, attributed to strong revenue growth and expanded adjusted gross margins [2] Financial Position - The company improved its balance sheet by reducing long-term debt by $48.3 million, enhancing liquidity [3] Future Guidance - Bioventus anticipates 2025 sales between $560 million and $570 million, compared to a consensus of $554.62 million, indicating an organic growth of approximately 6.1% to 8.0% when accounting for the divestiture of its Advanced Rehabilitation Business, which generated $45.4 million in revenue in 2024 [4] - The expected adjusted EPS for 2025 is projected to be between $0.64 and $0.68, exceeding Street estimates of $0.55 [4] - Adjusted EBITDA is forecasted to be between $112 million and $116 million, reflecting a 100 basis points increase in Adjusted EBITDA Margin compared to 2024 [5] Stock Performance - Following the earnings report, BVS stock increased by 21.9%, reaching $10.68 [5]